In a study conducted in human doxorubicin-resistant ovarian cancer cells, NRF2 level was found to be elevated compared to the control cell line, and silencing of NRF2 expression via siRNA restored drug sensitivity [42]. This evidence concerns the gene NFE2L2 and ovarian carcinoma.